vTv Therapeutics Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VTVT | NBP | VOGX | VYGR | TVGN | GNLX | |
|---|---|---|---|---|---|---|
| Market cap | 120.44M | 153.12M | 254.62M | 139.87M | 43.49M | 115.15M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -6.5 | -1.2 | — | -1.8 | — | -3.4 |
| Price/book | 4.8 | 0.8 | -50.7 | 0.9 | -1.5 | 7.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +39.66% | −78.22% | +31.85% | −54.42% | −81.00% | −51.80% |
| Today | −2.31% | −5.38% | −2.39% | −7.35% | −1.50% | −0.59% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All VTVT news ›vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026
The Manila Times vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026 New research spotlights hypoglycemia-related burdens in adults with type 1 diabetes using automated insulin delivery…
vTv Therapeutics Presents Data Showing Hypoglycemia Burden Persists in Adults with Type 1 Diabetes Using Automated Insulin Delivery Systems
Cadisegliatin is a novel oral therapy being evaluated as an adjunct to insulin for managing type 1 diabetes. Dr. Thomas Strack, Chief Medical Officer of vTv Therapeutics, presented the research on T1D at the inaugural CRC 2026. The…
vTv Therapeutics: Millennium reports 8.7% stake
Three parties report shared voting power over vTv Therapeutics (VTVT) shares in a passive stake amendment. Stock Titan - [SCHEDULE 13G/A] vTv Therapeutics Inc. Amended Passive Investment Disclosure vTv Therapeutics: Millennium reports 8.7%…
Financial Survey: vTv Therapeutics (NASDAQ:VTVT) vs. Milestone Pharmaceuticals (NASDAQ:MIST)
Posted by Defense World Staff on Oct 8th, 2026 Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) and vTv Therapeutics (NASDAQ:VTVT – Get Free Report) are both small-cap healthcare companies, but which is the better business? We…
vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
vTv Therapeutics (Nasdaq: VTVT) received FDA Orphan Drug Designation for HPPD, its investigational oral treatment for sickle cell disease. Preclinical studies at Augusta University used the Townes sickle cell disease mouse model. HPPD was…
vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Rating of "Moderate Buy" from Brokerages
Get Our Latest Stock Report on vTv Therapeutics Shares of VTVT stock opened at $30.03 on Wednesday. The company has a market cap of $118.32 million, a price-to-earnings ratio of -28.33 and a beta of 0.21. The stock has a 50 day simple…
vTv Therapeutics changes shareholder voting rules
vTv Therapeutics Inc. (VTVT) is a Nasdaq-listed late-stage biopharmaceutical company focused on oral small molecule drug candidates, led by cadisegliatin for diabetes. vTv Therapeutics changes shareholder voting rules Director nominees…
vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026
A glucokinase activator is a drug that boosts the activity of glucokinase, an enzyme that helps the liver and pancreas sense and lower blood sugar. Think of it as turning up the sensitivity of the body’s sugar thermostat so insulin release…
vTv Therapeutics (NASDAQ:VTVT) Upgraded to Hold at Wall Street Zen
vTv Therapeutics (NASDAQ:VTVT - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday, Wall Street Zen reports. Check Out Our Latest Analysis on…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
stocktitan.net3
-
marketbeat.com2
-
defenseworld.net1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.